Sign up Australia
Proactive Investors - Run By Investors For Investors

Isodiol’s BSPG subsidiary receives approval from UK regulators to manufacture CBD

Isodiol said the greenlight from the Medicines and Healthcare Products Regulatory Agency means it can now export its CBD around the world
cbd oil and cannabis flower
CBD is a non-psychoactive cannabinoid found in cannabis which has been touted as a possible treatment for things like pain and stress

BSPG Laboratories, a subsidiary of CBD consumer products maker Isodiol International Inc (CSE:ISOL; OTC:ISOLF), has received approval from UK regulators to manufacture cannabidiol (CBD).

Cannabidiol is a non-psychoactive cannabinoid found in cannabis, and research has suggested it could have several medical benefits such as pain and stress relief.

A first in the industry

With the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), BSPG’s natural CBD isolate can now be exported around the world, subject to pharmaceutical regulations.

“This approval validates the consistent quality of our pure, natural CBD isolate and the patented manufacturing processes,” said Isodiol’s Chief Executive Marcos Agramont.

“This event is a first in the industry and now enables Isodiol to focus on the development of CBD based drugs that will address a myriad of conditions that are affecting so many people around the world.”

He added: “With this approval, we will now rapidly advance our pharmaceutical and drug development divisions.”

Isodiol is currently building a state-of-the-art manufacturing facility which is expected to be up-and-running in the first quarter of 2019.

Once it is completed, the company expects to be able to produce around 20,000 kg of CBD each year, which will help it to “serve this newly created demand for CBD drug development, approved pharmaceutical applications, research, clinical studies, and clinical trials”.

Isodiol shares were down 4.7% to C$0.82 on Thursday morning.

View full ISOL profile View Profile

Isodiol International Timeline

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use